451 related articles for article (PubMed ID: 28668802)
1. Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study.
Berendsen MLT; van Maaren MC; Arts EEA; den Broeder AA; Popa CD; Fransen J
J Rheumatol; 2017 Sep; 44(9):1325-1330. PubMed ID: 28668802
[TBL] [Abstract][Full Text] [Related]
2. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
3. Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR cohort.
Gossec L; Paternotte S; Combe B; Meyer O; Dougados M
J Rheumatol; 2014 Jan; 41(1):41-6. PubMed ID: 24241481
[TBL] [Abstract][Full Text] [Related]
4. Association of anticyclic citrullinated peptide antibodies and/or rheumatoid factor status and clinical presentation in early arthritis: results from the ESPOIR cohort.
Mouterde G; Lukas C; Goupille P; Flipo RM; Rincheval N; Daurès JP; Combe B
J Rheumatol; 2014 Aug; 41(8):1614-22. PubMed ID: 25028372
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative.
Mackey RH; Kuller LH; Deane KD; Walitt BT; Chang YF; Holers VM; Robinson WH; Tracy RP; Hlatky MA; Eaton CB; Liu S; Freiberg MS; Talabi MB; Schelbert EB; Moreland LW
Arthritis Rheumatol; 2015 Sep; 67(9):2311-22. PubMed ID: 25988241
[TBL] [Abstract][Full Text] [Related]
6. Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry.
Huang S; He X; Doyle TJ; Zaccardelli A; Marshall AA; Friedlander HM; Blaustein RB; Smith EA; Cui J; Iannaccone CK; Mahmoud TG; Weinblatt ME; Dellaripa PF; Shadick NA; Sparks JA
Clin Rheumatol; 2019 Dec; 38(12):3401-3412. PubMed ID: 31410660
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies with hepatitis B and hepatitis C infection: Review.
Zengin O; Yıldız H; Demir ZH; Dağ MS; Aydınlı M; Onat AM; Kısacık B
Adv Clin Exp Med; 2017 Sep; 26(6):987-990. PubMed ID: 29068601
[TBL] [Abstract][Full Text] [Related]
8. Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.
Alemao E; Guo Z; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME
Semin Arthritis Rheum; 2018 Apr; 47(5):630-638. PubMed ID: 29241640
[TBL] [Abstract][Full Text] [Related]
9. Combination of anti-citrullinated protein antibodies and rheumatoid factor is associated with increased systemic inflammatory mediators and more rapid progression from preclinical to clinical rheumatoid arthritis.
Lingampalli N; Sokolove J; Lahey LJ; Edison JD; Gilliland WR; Holers VM; Deane KD; Robinson WH
Clin Immunol; 2018 Oct; 195():119-126. PubMed ID: 29842946
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of magnetic resonance imaging of the hand versus anticyclic citrullinated peptide antibody testing to confirm the diagnosis of clinically suspected early rheumatoid arthritis in the absence of rheumatoid factor and radiographic erosions.
Narváez J; Sirvent E; Narváez JA; Bas J; Gómez-Vaquero C; Reina D; Nolla JM; Valverde J
Semin Arthritis Rheum; 2008 Oct; 38(2):101-9. PubMed ID: 18221987
[TBL] [Abstract][Full Text] [Related]
11. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis.
Mewar D; Coote A; Moore DJ; Marinou I; Keyworth J; Dickson MC; Montgomery DS; Binks MH; Wilson AG
Arthritis Res Ther; 2006; 8(4):R128. PubMed ID: 16859535
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
Chang PY; Yang CT; Cheng CH; Yu KH
Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
14. The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis.
Ahmadi H; Jamshidi AR; Mahmoudi M; Cuzzocrea S; Fattahi MJ; Barati A; Rehm BHA; Matsuo H; Mirshafiey A
Curr Drug Discov Technol; 2017; 14(3):206-214. PubMed ID: 28325148
[TBL] [Abstract][Full Text] [Related]
15. Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis.
An J; Bider-Canfield Z; Kang J; Alemao E; Connolly SE; Lin AT; Cheetham TC
J Manag Care Spec Pharm; 2019 Apr; 25(4):469-477. PubMed ID: 30917075
[TBL] [Abstract][Full Text] [Related]
16. Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients.
Sulaiman FN; Wong KK; Ahmad WAW; Ghazali WSW
Medicine (Baltimore); 2019 Mar; 98(12):e14945. PubMed ID: 30896663
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of third generation anti-CCP antibodies in the diagnosis of rheumatoid arthritis from undifferentiated polyarthritis after 4 years of follow-up.
Caro-Oleas JL; Fernández-Suárez A; Reneses Cesteros S; Porrino C; Núñez-Roldán A; Wichmann Schlipf I
Clin Exp Rheumatol; 2008; 26(3):461-3. PubMed ID: 18578970
[TBL] [Abstract][Full Text] [Related]
18. Disordered Antigens and Epitope Overlap Between Anti-Citrullinated Protein Antibodies and Rheumatoid Factor in Rheumatoid Arthritis.
Zheng Z; Mergaert AM; Fahmy LM; Bawadekar M; Holmes CL; Ong IM; Bridges AJ; Newton MA; Shelef MA
Arthritis Rheumatol; 2020 Feb; 72(2):262-272. PubMed ID: 31397047
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of rheumatoid factor and anti-citrullinated peptide antibodies in relation to rheumatological manifestations in patients with leprosy from Southern Brazil.
Dionello CF; Rosa Utiyama SR; Radominski SC; Stahlke E; Stinghen ST; de Messias-Reason IJ
Int J Rheum Dis; 2016 Oct; 19(10):1024-1031. PubMed ID: 26250118
[TBL] [Abstract][Full Text] [Related]
20. Anti-Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis.
Westerlind H; Rönnelid J; Hansson M; Alfredsson L; Mathsson-Alm L; Serre G; Cornillet M; Holmdahl R; Jakobsson PJ; Skriner K; Klareskog L; Saevarsdottir S; Askling J
Arthritis Rheumatol; 2020 Oct; 72(10):1658-1667. PubMed ID: 32475073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
